Kingdon Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kingdon Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.6M	Hold	2,500,000	–	–	5.6%	2
2026 Q1	$58.4M	Buy	2,500,000 +150,000	+6%	+$3.26M	6.41%	2
2025 Q4	$49.4M	Sell	2,350,000 -150,000	-6%	-$2.62M	5.87%	2
2025 Q3	$38.5M	Buy	2,500,000 +400,000	+19%	+$5.24M	4.77%	2
2025 Q2	$19.7M	Buy	2,100,000 +100,000	+5%	+$1.1M	2.65%	7
2025 Q1	$24.6M	Hold	2,000,000	–	–	2.6%	3
2024 Q4	$26.4M	Buy	2,000,000 +1,000,000	+100%	+$17.1M	3.77%	2
2024 Q3	$19.3M	Buy	1,000,000 +105,007	+12%	+$2.17M	2.13%	8
2024 Q2	$18.4M	Hold	894,993	–	–	1.97%	14
2024 Q1	$21.3M	Buy	894,993 +148,700	+20%	+$3.32M	2.33%	6
2023 Q4	$16.1M	Buy	+746,293	New	+$11.5M	2.02%	18

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Kingdon Capital Management's SNDX Position: Q2 2026 in Review

Kingdon Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 2,500,000 shares worth $54.6M. The position accounts for 5.6% of the portfolio, ranked #2.

Kingdon Capital Management first reported a position in SNDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $58.4M in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Kingdon Capital Management held 2,500,000 shares of Syndax Pharmaceuticals worth $54.6M as of Q2 2026.
Kingdon Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
Syndax Pharmaceuticals made up 5.6% of Kingdon Capital Management's portfolio in Q2 2026, its #2 holding.
Kingdon Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Kingdon Capital Management's Syndax Pharmaceuticals position peaked at $58.4M in Q1 2026.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.